Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

Journal of the American Academy of Dermatology

Volumn 66, Issue 2, 2012, Pages 241-251

  Gordon, Kenneth ^a   Papp, Kim ^b   Poulin, Yves ^c   Gu, Yihua ^d   Rozzo, Stephen ^d   Sasso, Eric H ^d  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c Centre Dermatologique du Quebec Metropolitain   (Canada)

^d ABBOTT LABORATORIES   (United States)

Author keywords

adalimumab; anti tumor necrosis factor therapy; clinical trial; efficacy; long term treatment; open label; psoriasis; safety

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; ARTICLE; CANDIDIASIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84855849399     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.12.005     Document Type: Article

References (25)

1. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741 (Pubitemid 44547793)
2. A. Leon, A. Nguyen, J. Letsinger, and J. Koo An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options Expert Opin Pharmacother 8 2007 617 632 (Pubitemid 46547015)
3. A.B. Gottlieb, C. Chao, and F. Dann Psoriasis comorbidities J Dermatolog Treat 19 2008 5 21 (Pubitemid 351252710)
4. A.B. Kimball, D. Gladman, J.M. Gelfand, K. Gordon, E.J. Horn, and N.J. Korman National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening J Am Acad Dermatol 58 2008 1031 1042
5. D.G. Federman, M. Shelling, S. Prodanovich, C.G. Gunderson, and R.S. Kirsner Psoriasis: an opportunity to identify cardiovascular risk Br J Dermatol 160 2009 1 7
6. A.B. Kimball, A. Guerin, D. Latremouille-Viau, A.P. Yu, S. Gupta, and Y. Bao Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis Am J Med 123 2010 350 357
7. K. Reich, F.O. Nestle, K. Papp, J.P. Ortonne, R. Evans, and C. Guzzo Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial Lancet 366 2005 1367 1374 (Pubitemid 41443403)
8. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 31 e1-15
9. S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726 (Pubitemid 46955730)
10. C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, and Y. Wang Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674 (Pubitemid 351671883)
11. K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, and N. Yeilding Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684 (Pubitemid 351671884)
12. A. Menter, C.L. Leonardi, W. Sterry, J.D. Bos, and K.A. Papp Long-term management of plaque psoriasis with continuous efalizumab therapy J Am Acad Dermatol 54 Suppl 2006 S182 S188 (Pubitemid 43238301)
13. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115 (Pubitemid 350298146)
14. K. Gordon, R. Blum, K. Papp, R. Matheson, C. Bolduc, and T. Hamilton Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial Psoriasis Forum 13 2007 4 11
15. K.B. Gordon, R.G. Langley, C. Leonardi, D. Toth, M.A. Menter, and S. Kang Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study J Am Acad Dermatol 55 2006 598 606 (Pubitemid 44436647)
16. J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, and J.P. Ortonne Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566 (Pubitemid 351239154)
17. Humira [package insert] 2011 Abbott Laboratories North Chicago, IL
18. European Medicines Agency. Assessment report for Stelara. DocRef: EMEA/CHMP/29255/2009. Available at: URL: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Public-assessment-report/human/000958/WC500058511.pdf. Accessed January 27, 2011.
19. A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850 (Pubitemid 351509656)
20. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, and A.M. Nakanishi A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312 (Pubitemid 40933433)
21. A. Asahina, H. Nakagawa, T. Etoh, and M. Ohtsuki Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study J Dermatol 37 2010 299 310
22. J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, and W. Kirch Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials Br J Dermatol 159 2008 513 526
23. J.W. Dharamsi, M. Bhosle, R. Balkrishnan, B.A. Yentzer, and S.R. Feldman Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumor necrosis factor-alpha inhibitors for patients with severe psoriasis Br J Dermatol 161 2009 605 616
24. C.H. Smith, A.V. Anstey, J.N. Barker, A.D. Burden, R.J. Chalmers, and D.A. Chandler British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009 Br J Dermatol 161 2009 987 1019
25. R.G. Langley, B.E. Strober, Y. Gu, S.J. Rozzo, and M.M. Okun Benefit-risk assessment of tumor necrosis factor antagonists in the treatment of psoriasis Br J Dermatol 162 2010 1349 1358